anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A PRP separator-concentrator comprising a housing (2), a separation assembly, and a concentration assembly. The concentration assembly has a concentration sump (162). An axially concentric rigid stationary outlet tube is secured to the housing and extends through the separation assembly to the sump. The separation assembly is attached to and positioned above the concentration assembly to form a combined separator-concentrator assemblage that is rotatable about the outlet tube. The separation assembly includes a separation chamber lined with a depth filter having pores and passageways that are sized to receive and entrap erythrocytes during centrifuging. The concentration chamber has a floor for supporting desiccated beads and a wall with at least one opening closed with a screen (188). PRP concentrate is produced by contacting PRP with desiccated beads (19) while the beads are stirred with a stationary rake, and rotating the concentration chamber at centrifugal speeds to separate PRP concentrate from the beads.
BACKGROUND: After an ankle sprain, the ligament and joint capsule are damaged, and as a result, proprioceptive sense is damaged, causing a feeling of giving away in the ankle and resulting in recurrent sprains. Given the relevant studies, it has been seen that people with chronic ankle instability (CAI) commonly have deficits in joint position sense and reinjury risks. Joint position sense plays an important role in ankle control, thereby reducing the risk of injury. Therefore, this study aims to compare the effects of balance and strength training on ankle proprioception in people with CAI.
METHODS: This single-blind randomized controlled study included 29 volunteer participants (21 women and eight men) aged 18 to 30 years. Participants with a Cumberland ankle instability scale score less than or equal to 24 were randomly divided into two treatment groups: strength training (n = 14) and balance training (n = 15). Y balance test, joint position, and vibration sense were evaluated at the beginning and end of the treatment. "Hop to stabilization" exercises were applied to the balance group and resistive bands exercises to the strength group, which were performed for 6 weeks, 35 minutes per day, two times per week.
RESULTS: There was no significant difference between the two groups in the anterior, posterolateral, and posteromedial directions of the Y balance test (P = .89, P = .50, and P = .34, respectively), but the strength training group showed significant improvement in ankle proprioception (140°) and vibration sense (fifth finger) (P < .001), and the post hoc Cohen's d effect size values were medium (.52) and small (.25), respectively.
CONCLUSIONS: The findings of this study show that strengthening and balance exercises have similar effects on dynamic balance, but strengthening exercises are more effective in improving joint position and vibration sense. Given the positive effects of both exercise programs, it is recommended to implement the two interventions separately or together for CAI rehabilitation.
FIELD: biotechnology, medicine, pharmacy. SUBSTANCE: preparation shows immuno-stimulating and adaptogenic effects. Preparation has wheat embryo an aqueous-spirituous extract in the following ratio of components, wt.-%: ethyl alcohol, 30-40; water, 58-68; tocopherols, 0.0003-0.001; vitamin B 6 , 0.005-0.01 and other hydrated components of wheat embryos, the balance. Method of preparing the preparation involves embryos extraction with 30-50% ethyl alcohol aqueous solution at the room temperature for at least 20 min. Then extract is separated by decanting and/or filtration followed by its heating at 60-70 C for at least 40 min. Liquid fraction is separated and purified by filtration through activated carbon. Invention ensures to obtain effective preparation used for normalization of immune and cardiovascular systems function. EFFECT: improved method of preparing, valuable medicinal properties. 6 cl, 4 tbl, 2 ex
A portable osmotic pump, having two pouches (4,3) in pressure-transmitting relationship, the first (4) containing a pumped fluid, such as infusate (5), and the second (3), a driving fluid (36). The driving fluid is created and pressurized by activation of an osmotic pump, and the rate of infusion is controlled by a semipermeable membrane (10). Activation can be by rupturing a seal (11) or by opening a closed tube (58) to permit permeant (2) to contact the semipermeable membrane. Pulses of the pumped fluid can be achieved by delivery pulses of the permeant to the second pouch. The pouches can be designed to resist collapse of the first pouch by external forces on the pumped liquid, such as gravity, movement of the first pouch and negative pressures applied to the pumped liquid. The infusate pouch is manufactured separately and can be stored apart from the rest of the system.
* Healthcare professionals who prescribe FENTORA for outpatients must enroll in the TIRF REMS and comply with the requirements of the REMS to ensure safe use of FENTORA [see Warnings and Precautions (5.7)].
  * Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5)]. Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of FENTORA for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks.
  * It is important to minimize the number of strengths available to patients at any time to prevent confusion and possible overdose.
  * There is variability in the opioid analgesic dose and duration needed to adequately manage pain due both to the cause of pain and to individual patient factors. Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse [see Warnings and Precautions (5.1)].
  * Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with FENTORA. Consider this risk when selecting an initial dose and when making dose adjustments [see Warnings and Precautions (5)].
  * Instruct patients and caregivers to take steps to store FENTORA securely and to properly dispose of unused FENTORA as soon as no longer needed [see Warnings and Precautions (5.1, 5.3)].
  * FENTORA is not bioequivalent with other fentanyl products. Do not convert patients on a mcg per mcg basis from other fentanyl products. There are no conversion directions available for patients on any other fentanyl products other than ACTIQ (Note: This includes oral, transdermal, or parenteral formulations of fentanyl.) [see Warnings and Precautions (5.5)].
  * FENTORA is NOT a generic version of any other transmucosal fentanyl product [see Warnings and Precautions (5.5)].
OBJECTIVE: Our study aimed to investigate the analgesic efficacy of nebulized ketamine in managing acute moderate-to-severe musculoskeletal pain in older emergency department (ED) patients compared with intravenous (IV) morphine.
METHODS: This was a non-inferiority, double-blind, randomized controlled trial conducted at a single medical centre. The patients aged 65 and older, who presented at the ED musculoskeletal pain within 7 days and had a pain score of 5 or more on an 11-point numeric rating scale (NRS), were included in the study. The outcomes were a comparison of the NRS reduction between nebulized ketamine and IV morphine 30 minutes after treatment, incidence of adverse events and rate of rescue therapy.
RESULTS: The final study included 92 individuals, divided equally into two groups. At 30 minutes, the difference in mean NRS between the nebulized ketamine and IV morphine groups was insignificant (5.2 versus 5.7). The comparative mean difference in the NRS change from baseline between nebulized ketamine and IV morphine [-1.96 (95% confidence interval-CI: -2.45 to -1.46) and -2.15 (95% CI: -2.64 to -1.66) = 0.2 (95% CI: -0.49 to 0.89)] did not exceed the non-inferiority margin of 1.3. The rate of rescue therapy did not differ between the groups. The morphine group had considerably higher incidence of nausea than the control group (zero patients in the ketamine group versus eight patients (17.4%) in the morphine group; P = 0.006).
CONCLUSIONS: Nebulized ketamine has non-inferior analgesic efficacy compared with IV morphine for acute musculoskeletal pain in older persons, with fewer adverse effects.
Students will participate in all 3 components of MyFF@school for a total of 32 weeks; 1-hour of SSG thrice weekly plus 30 to 45 minutes of either nutrition or psychology classes once a week. All students including those in the control arm will be assessed at baseline, week-16 and at end of the study. They will undergo anthropometric measurements, body fat assessment, clinical examination and fitness test by modified Harvard step-test.
Polymeric elastomers are widely utilized in implantable biomedical devices. Nevertheless, the implantation of these elastomers can provoke a robust foreign body response (FBR), leading to the rejection of foreign implants and consequently reducing their effectiveness in vivo. Building effective anti-FBR coatings on those implants remains challenging. Herein, we introduce a coating-free elastomer with superior immunocompatibility. A super-hydrophilic anti-fouling zwitterionic layer can be generated in situ on the surface of the elastomer through a simple chemical trigger. This elastomer can repel the adsorption of proteins, as well as the adhesion of cells, platelets, and diverse microbes. The elastomer elicited negligible inflammatory responses after subcutaneous implantation in rodents for 2 weeks. No apparent fibrotic capsule formation was observed surrounding the elastomer after 6 months in rodents. Continuous subcutaneous insulin infusion (CSII) catheters constructed from the elastomer demonstrated prolonged longevity and performance compared to commercial catheters, indicating its great potential for enhancing and extending the performance of various implantable biomedical devices by effectively attenuating local immune responses. STATEMENT OF SIGNIFICANCE: The foreign body response remains a significant challenge for implants. Complicated coating procedures are usually needed to construct anti-fibrotic coatings on implantable elastomers. Herein, a coating-free elastomer with superior immunocompatibility was achieved using a zwitterionic monomer derivative. A pure zwitterionic layer can be generated on the elastomer surface through a simple chemical trigger. This elastomer significantly reduces protein adsorption, cell and bacterial adhesion, and platelet activation, leading to minimal fibrotic capsule formation even after six months of subcutaneous implantation in rodents. CSII catheters constructed from the PQCBE-H elastomer demonstrated prolonged longevity and performance compared to commercial catheters, highlighting the significant potential of PQCBE-H elastomers for enhancing and extending the performance of various implantable biomedical devices.
The healing of traumatic wounds, to include burns, can be compromised by the presence of infection so efforts are made to prevent or diagnose infection early in order to mitigate the negative impact on healing. Electric stimulation has previously been shown to have both bacteriostatic and bactericidal effects in wounds. Until now, administering low intensity electric field/micro-current as a therapy to mitigate biofilm infection and to improve wound healing was not feasible. In this study the investigators will use Procellera® , a FDA approved fabric based wireless electroceutical dressing (WED) consisting of a silver-zinc electro-couple for the prevention of wound biofilm formation. The dressing generates a low electric field (\~1V) upon activation by a moist environment, which mitigates biofilm formation and promotes wound healing. The objectives of the study are to evaluate the efficacy of a wireless electroceutical dressing to prevent the formation or disrupting existing biofilms. The investigators will conduct a prospective, randomized controlled clinical trial using the Procellera® dressing compared to the standard of care. Treatment sites will be randomized to either receiving Procellera® or the standard of care treatment. Objective measurements and assessments will be completed during subject follow-up visits for up to one month post treatment. This includes biopsies to calculate bacterial load by assessing colony forming unit (CFU) count and bacterial film visualization using scanning electron microscopy, histology, clinical assessment of infection, Transepidermal Water Loss (TEWL) and wound photography.
Participants received panitumumab as an intravenous (IV) infusion at a dose of 6 mg/kg plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-fluorouracil (5-FU), leucovorin and irinotecan. Treatment was administered in cycles every two weeks.
The invention relates to the technical field of tea bags and particularly relates to a tea bag containing moringa tree leaves and a preparing method thereof. A formula of the tea bag comprises 1-2.8 parts by mass of cyclocarya paliurus leaves, 0.1-1.0 part by mass of the moringa tree leaves and 0.1-0.5 part of Liubao tea leaves. The preparing method of the tea bag is also provided. The preparing method includes smashing, mixing, granulating, packing into a bag, and the like. The tea bag can effectively reduce blood sugar for human bodies and regulate overall functions of a human body. The tea bag is ideal in quality, flavor, taste, color and fragrance and is suitable for diabetic patients.
The invention relates to the field of traditional Chinese medicines, and discloses two traditional Chinese medicine formulas for treating depression and anxiety by alternately taking, namely a Hui Tian formula and a deficiency labor formula. The Huitian formula warms and tonifies spleen and kidney, promotes appetite, and stabilizes mind; the consumptive disease prescription soothes liver and relieves depression, tonifies qi and strengthens kidney, and promotes spirit. The prevalence rate of depression and anxiety disorder is high, the harm is large, the recurrence rate is high, and effective treatment medicines with few side effects are lacked. Clinically, most of depression and anxiety patients have the symptoms of deficiency and impairment of liver and gallbladder, usually the left and right kidney vessels are deep, and the patients are difficult to take care of all the pathogenesis only by using one prescription. The two traditional Chinese medicine formulas of the item can soothe liver and relieve depression, and simultaneously can tonify qi, invigorate spleen, tonify kidney and replenish essence. The consumptive disease formula is biased to the left-tonifying way, the return formula is biased to the right-tonifying way, and the two formulas are alternately taken every day, so that qi, blood and yin and yang on the left side and the right side can be balanced and supplemented while the liver is soothing and qi stagnation is relieved; not only relieves the symptoms of depression and anxiety, but also can promote appetite and improve the qi and blood level of patients, and has little side effect on human bodies.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of MIPLYFFA was evaluated in a randomized, double-blind, placebo-controlled, 12-month trial (Trial 1), which included 50 patients 2 to 19 years old with NPC [see Clinical Studies ( 14)] . Patients received weight-adjusted doses of MIPLYFFA (31 to 124 mg orally three times daily); 28 of the patients were exposed to MIPLYFFA for one year. In Trial 1, 78% of patients received miglustat. Forty-one out of 50 patients that were enrolled in Trial 1 continued into an open-label extension trial, which included 39 patients treated with MIPLYFFA for more than 1 year, 34 patients treated with MIPLYFFA for more than 2 years, and 17 patients treated with MIPLYFFA for more than 5 years. 

The most common adverse reactions in Trial 1 (≥ 15%) in MIPLYFFA-treated patients who also received miglustat were upper respiratory tract infection, diarrhea, and decreased weight. Three (6%) of the MIPLYFFA-treated patients had the following adverse reactions that led to withdrawal from Trial 1: increased serum creatinine (one patient), and progressive urticaria and angioedema (two patients). Serious adverse reactions reported in MIPLYFFA-treated patients in Trial 1 were hypersensitivity reactions including urticaria and angioedema.

Table 1shows common adverse reactions in Trial 1 that occurred in at least 8% of MIPLYFFA-treated patients who also received miglustat. 

Decreased Weight

Adverse reactions of decreased weight were observed in four patients, who were also receiving concomitant miglustat during the trial. The decrease in weight resolved in all but one of the patients. The mean duration of the weight decrease was 33 days and ranged from 22 to 60 days. One patient had two separate instances of weight loss during the trial, lasting 22 and 24 days respectively. The mean weight loss was approximately 6% from baseline in all patients and MIPLYFFA administration was not interrupted in any patient.

Laboratory Findings

Thrombocytopenia:Thrombocytopenia was observed in three patients during the trial, all of whom were receiving miglustat for six months or longer at the time of enrollment. In two of these patients, the thrombocytopenia was present at baseline and persisted throughout the trial. In the other patient, the thrombocytopenia developed and resolved during the trial. 

Increased Creatinine:Across clinical trials in patients with NPC, healthy subjects, and patients with other diseases, increases in serum creatinine (mean increase was 10-20%) occurred mainly within the first month of dosing and were reversible upon treatment discontinuation.
Gel mass consists essentially of a humectant, pref. glycerol, dissolved in an aq. colloidal solution of hectorite clay which is present in an amount sufficient for the formation of a gel mass. An alternative type of gel consists essentially of an aq. colloidal soln. of hectorite clay in an amount sufficient for the formation of a gel mass and a peptisator, pref. a water-soluble ammonium, potassium or sodium salt of a condensed phosphoric acid, the gel being obtained by heating the liquid aqueous colloidal soln. to a temp. at which it is converted into a gel. Pref. a pigment or filled-capsules, advantageously contg. a pigment, are suspended int he gels. The gels are useful for the prodn. of toothpastes, cosmetics, foodstuffs etc. They are also useful as glass-cleaning agents and agents for removing carbonaceous dirt from surfaces. The gels can easily be removed from surfaces e.g. the skin by rinsing with water, which is advantageous when used in toothpastes and cosmetics and when used as a cleaning agent. Toothpastes contg. the gels have good plaque-removing props., and leave a pleasant fresh feeling in the mouth. The gels can also be advantageously used as the basis of candies etc.
FIELD: pharmacology. SUBSTANCE: composition has therapeutically active quantity of erythromycin and special purpose admixtures in % from erythromycin mass like starch 40.95-71.33, polyvinyl pyrrolidone3.53-4.77, Twin-80 2.78-3.84 and a stearate salt 1.39-1.95. Nucleus tablet is coated with film-building shell manufactured from a mixture of acetylphthalyl cellulose, castor oil and titanium dioxide. Method involves applying humid granulation followed with coating nucleus tablet with filmbuilding composition. Application time is no less than 2 years. EFFECT: easy release of active ingredient; high level of bioavailability. 8 cl, 1 tbl
Persistent infection with high-risk human papillomavirus (HR-HPV) is the main cause of cervical cancer. These chronic infections are characterized by high expression of the HPV E6 and E7 oncogenes and the absence of the L1 and L2 capsid proteins. The regulation of HPV gene expression plays a crucial role in both the viral life cycle and rare oncogenic events. Alternative splicing of HPV mRNA is a key mechanism in post-transcriptional regulation. Through alternative splicing, HPV mRNA is diversified into various splice isoforms with distinct coding potentials, encoding multiple proteins and influencing the expression of HPV genes. The spliced mRNAs derived from a donor splicing site within the E6 ORF and one of the different acceptor sites located in the early mRNA contain E6 truncated mRNAs, named E6*. E6* is one of the extensively studied splicing isoforms. However, the role of E6* proteins in cancer progression remains controversial. Here, we reviewed and compared the alternative splicing events occurring in the genomes of HR-HPV and LR-HPV. Recently, new HPV alternative splicing regulatory proteins have been continuously discovered, and we have updated the regulation of HPV alternative splicing. In addition, we summarized the functions of known splice isoforms from three aspects: anti-tumorigenic, tumorigenic, and other cancer-related functions, including not only E6*, but also E6^E7, E8^E2, and so on. Comprehending their contributions to cancer development enhances insights into the carcinogenic mechanisms of HPV and explores the potential utility of alternative splicing in the diagnosis and treatment of cervical cancer.
Minimal sedation (and early extubation if possible). Fever management with a feedback-controlled device if temperature above 37.7°C. A mean arterial pressure target of \>65mmHg.
Participants will receive chlorambucil and obinutuzumab (G-Clb) for 6 cycles. Participants will receive obinutuzumab, 1000 mg intravenously (IV) on Days 1, 8 and 15 of Cycle 1, and on Day 1 of Cycles 2 to 6 and chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight, on Days 1 and 15 of Cycles 1 to 6. Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.
Systems and methods are disclosed for remotely controlling a main processing console of an ultrasound system. In various embodiments, an ultrasound remote controller can be used to remotely control a main processing console of an ultrasound system. The ultrasound remote controller can include a user interface controller configured to provide one or more ultrasound control functions to a user remote from the main processing console. The control functions can be used to remotely control operation of the main console. Further, the user interface controller can be configured to receive input for the one or more ultrasound control functions from the user. The ultrasound remote controller can include a communication interface configured to transmit operational instructions to the main processing console for remotely controlling the operation of the main processing console through the ultrasound remote controller based on the user input for the one or more ultrasound control functions.